Dr. Poulami Chaudhuri
CEO, CSO, Co-founder, HELEX
India faces a significant healthcare challenge due to its high prevalence of genetic diseases, which are exacerbated by factors such as consanguineous marriages and a diverse genetic landscape. Disorders like thalassemia, sickle cell anaemia, and cystic fibrosis impact a large portion of the population, with many treatments remaining financially inaccessible. While affluent individuals often benefit from preventive measures such as genetic counselling and comprehensive prenatal diagnostics, these resources are not universally available, and routine screening typically focuses only on conditions like Down syndrome.
Historically, medical treatments have concentrated on addressing the symptoms of genetic disorders, primarily by targeting the resultant proteins. However, the advent of genetic sequencing and genome editing technologies, such as CRISPR, has revolutionized this approach. CRISPR technology enables precise modifications to the genome, offering the potential for permanent treatment with a single dose. This innovative approach involves three key components: the cutting enzyme (often referred to as the
“scissors”), the guide RNA (the “navigator” that directs where the cut should occur), and a vector (viral or non-viral) that delivers these tools to the target cells. By directly correcting genetic defects, CRISPR technology opens the door to personalized medicine, where treatments are tailored to an individual’s unique genetic profile.
Despite its revolutionary potential, CRISPR is a double-edged sword. Ethical concerns have arisen, such as the controversial case of gene-edited embryos in China, where genetic modifications aimed at preventing HIV raised questions about unintended consequences and long-term effects. Responsible use of CRISPR technology is crucial, emphasizing the need for careful ethical considerations. Currently, FDA-approved CRISPR-based therapies for major genetic diseases like sickle cell anaemia and beta-thalassemia come with staggering costs, often exceeding $1 million per patient. This high price poses a significant challenge even in well-established healthcare systems like those in the US and UK, making it particularly daunting for average citizens in India, where the cost of such therapies is prohibitively high.
To address these challenges, innovations in delivery systems, such as lipid nanoparticles (LNPs), are promising. LNPs, used effectively in COVID-19 mRNA vaccines, offer scalable, safer, and less immunogenic alternatives to traditional viral vectors for gene therapies. As LNP-based RNA therapies become more prevalent, they represent the future of advanced therapeutics.
India's pharmaceutical industry, renowned as the "pharmacy of the world" for its production of affordable generic medicines, possesses a highly skilled workforce and a large domestic market. Embracing advanced technologies like gene editing could significantly alleviate disease symptoms and address the underlying genetic causes of disorders. By championing these innovations and fostering a supportive ecosystem for research and development, India has the opportunity to become a global leader in healthcare. This could revolutionize the treatment of genetic diseases, making life-saving therapies more accessible and affordable, and ultimately saving millions of lives.
As India continues to advance in the realm of genetic medicine, it holds the potential to drive transformative changes in global healthcare, highlighting the critical importance of continued innovation and ethical responsibility in the pursuit of medical breakthroughs.
I currently lead a gene-editing therapeutic company called Helex, with a vision that goes beyond producing high-quality genomic medicines—we aim to make these therapies accessible, particularly in countries like India. In 2021, a news article reporting the tragic loss of 50 children due to delays in gene therapy funding struck a chord with me. It was a stark reminder of the urgent need for change.
With a background in molecular biology from King’s College London, where I earned both my MSc and PhD focusing on non-viral vector delivery systems, and further expertise in computational biology from my postdoctoral research at TCS Innovation Labs—where I investigated the 3D genome structure and its role in disease—I was determined to create therapies that are not only precise and safe but also affordable. My upbringing in Defence schools and Kendriya Vidyalaya was humble, but my passion for mathematics and science from my 11th and 12th grades laid the groundwork for my current work.
The fundamental lessons I learned have shaped the innovations I am developing today. Just as I discovered my own potential to contribute meaningfully to others’ lives, each of you has untapped potential within you. It’s about uncovering that inner gem and finding your path to make a difference.
